Literature DB >> 23118099

High dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancer.

A Challapalli1, E Jones, C Harvey, G O Hellawell, S A Mangar.   

Abstract

The technological advances in real-time ultrasound image guidance for high dose rate (HDR) prostate brachytherapy places this treatment modality at the forefront of innovation in radiotherapy. This review article will explore the rationale for HDR brachytherapy as a highly conformal method of dose delivery and safe dose escalation to the prostate, in addition to the particular radiobiological advantages it has over low dose rate and external beam radiotherapy. The encouraging outcome data and favourable toxicity profile will be discussed before looking at emerging applications for the future and how this procedure will feature alongside stereotactic radiosurgery.

Entities:  

Mesh：

Year:  2012        PMID： 23118099      PMCID： PMC3746400          DOI： 10.1259/bjr/15403217

Source DB:  PubMed          Journal:  Br J Radiol        ISSN： 0007-1285            Impact factor:   3.039


  75 in total

1.  3-D conformal treatment of prostate cancer to 74 Gy vs. high-dose-rate brachytherapy boost: a cross-sectional quality-of-life survey.

Authors:  Dirk Vordermark; Jörn Wulf; Klaus Markert; Kurt Baier; Oliver Kölbl; Gabriele Beckmann; Klaus Bratengeier; Michael Noe; Georg Schön; Michael Flentje
Journal:  Acta Oncol       Date:  2006       Impact factor: 4.089

2.  Health related quality of life outcomes after radical prostatectomy: attention to study design and the patient-based importance of single-surgeon studies.

Authors:  Bruce L Dalkin; Bea Anne Christopher; Darla Shawler
Journal:  Urol Oncol       Date:  2006 Jan-Feb       Impact factor: 3.498

Review 3.  High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.

Authors:  D Jeffrey Demanes; Rodney R Rodriguez; Lionel Schour; David Brandt; Gillian Altieri
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-04-01       Impact factor: 7.038

4.  Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience.

Authors:  Brian Lee; Katsuto Shinohara; Vivian Weinberg; Alexander R Gottschalk; Jean Pouliot; Mack Roach; I-Chow Hsu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-12-29       Impact factor: 7.038

5.  High dose rate iridium-192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer.

Authors:  Y S Chin; J Bullard; L Bryant; P Bownes; P Ostler; P J Hoskin
Journal:  Clin Oncol (R Coll Radiol)       Date:  2006-08       Impact factor: 4.126

6.  Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer.

Authors:  Michael A Izard; Richard L Haddad; Gerald B Fogarty; Adrian Rinks; Timothy Dobbins; Philip Katelaris
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-01       Impact factor: 7.038

7.  Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer.

Authors:  Yoshiya Yamada; Sudershan Bhatia; Marco Zaider; Gilad Cohen; Machele Donat; James Eastham; Farhang Rabbani; Karen Schupak; James Lee; Boris Mueller; Michael J Zelefsky
Journal:  Brachytherapy       Date:  2006 Jul-Sep       Impact factor: 2.362

8.  High dose rate brachytherapy as a boost for the treatment of localized prostate cancer.

Authors:  Thinh P Phan; A M Nisar Syed; Ajmel Puthawala; Anil Sharma; Farhan Khan
Journal:  J Urol       Date:  2007-01       Impact factor: 7.450

9.  Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?

Authors:  Razvan M Galalae; Alvaro Martinez; Nils Nuernberg; Gregory Edmundson; Gary Gustafson; Jose Gonzalez; Bernhard Kimming
Journal:  Strahlenther Onkol       Date:  2006-03       Impact factor: 3.621

10.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.

Authors:  David P Dearnaley; Matthew R Sydes; John D Graham; Edwin G Aird; David Bottomley; Richard A Cowan; Robert A Huddart; Chakiath C Jose; John Hl Matthews; Jeremy Millar; A Rollo Moore; Rachel C Morgan; J Martin Russell; Christopher D Scrase; Richard J Stephens; Isabel Syndikus; Mahesh K B Parmar
Journal:  Lancet Oncol       Date:  2007-06       Impact factor: 41.316
View more
  13 in total

1.  Prostate CT segmentation method based on nonrigid registration in ultrasound-guided CT-based HDR prostate brachytherapy.

Authors:  Xiaofeng Yang; Peter Rossi; Tomi Ogunleye; David M Marcus; Ashesh B Jani; Hui Mao; Walter J Curran; Tian Liu
Journal:  Med Phys       Date:  2014-11       Impact factor: 4.071

2.  Male urogenital disorders.

Authors:  C J Harvey
Journal:  Br J Radiol       Date:  2012-11       Impact factor: 3.039

3.  BJR brachytherapy dosimetry special feature.

Authors:  A L Palmer
Journal:  Br J Radiol       Date:  2014-07-23       Impact factor: 3.039

4.  Multi-needle Localization with Attention U-Net in US-guided HDR Prostate Brachytherapy.

Authors:  Yupei Zhang; Yang Lei; Richard L J Qiu; Tonghe Wang; Hesheng Wang; Ashesh B Jani; Walter J Curran; Pretesh Patel; Tian Liu; Xiaofeng Yang
Journal:  Med Phys       Date:  2020-04-03       Impact factor: 4.071

5.  High-dose-rate interstitial brachytherapy in combination with androgen deprivation therapy for prostate cancer: are high-risk patients good candidates?

Authors:  Ken Yoshida; Hideya Yamazaki; Tadashi Takenaka; Tadayuki Kotsuma; Mineo Yoshida; Koji Masui; Yasuo Yoshioka; Yoshifumi Narumi; Toshitsugu Oka; Eiichi Tanaka
Journal:  Strahlenther Onkol       Date:  2014-05-17       Impact factor: 3.621

6.  Psychosexual experiences of men following radiotherapy for prostate cancer in Johannesburg, South Africa.

Authors:  Matheko N Phahlamohlaka; Sibusiso Mdletshe; Heather Lawrence
Journal:  Health SA       Date:  2018-10-09

7.  High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up.

Authors:  Hiromichi Ishiyama; Takefumi Satoh; Masashi Kitano; Ken-ichi Tabata; Shouko Komori; Masaomi Ikeda; Itaru Soda; Shinji Kurosaka; Akane Sekiguchi; Masaki Kimura; Shogo Kawakami; Masatsugu Iwamura; Kazushige Hayakawa
Journal:  J Radiat Res       Date:  2013-11-11       Impact factor: 2.724

8.  Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer.

Authors:  Hideyasu Tsumura; Takefumi Satoh; Hiromichi Ishiyama; Ken-Ichi Tabata; Shouko Komori; Akane Sekiguchi; Masaomi Ikeda; Shinji Kurosaka; Tetsuo Fujita; Masashi Kitano; Kazushige Hayakawa; Masatsugu Iwamura
Journal:  J Contemp Brachytherapy       Date:  2016-04-29

Review 9.  Current and Future Theranostic Applications of the Lipid-Calcium-Phosphate Nanoparticle Platform.

Authors:  Andrew B Satterlee; Leaf Huang
Journal:  Theranostics       Date:  2016-04-27       Impact factor: 11.556

10.  Implantation of computed tomography-guided Iodine-125 seeds in combination with chemotherapy for the treatment of stage III non-small cell lung cancer.

Authors:  Xiaodong Huo; Bin Huo; Huixing Wang; Lei Wang; Qiang Cao; Guangjun Zheng; Junjie Wang; Shude Chai; Zuncheng Zhang; Kuo Yang; Yuanjie Niu; Haitao Wang
Journal:  J Contemp Brachytherapy       Date:  2017-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.